
Opinion|Videos|May 15, 2024
ARASENS Trial- Darolutamide in mHSPC
Dr. Shore will provide an overview of the Phase 3 ARASENS trial, which evaluated the efficacy of the androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel in hormone-sensitive prostate cancer patients. He will discuss the potential benefits of this combination in patients with high tumor burden mHSPC.
Advertisement
Episodes in this series

Advertisement
Related to this article

Oncologists discuss long-term ibrutinib use, cardiovascular risks with BTK inhibitors, and emerging fixed-duration acalabrutinib-venetoclax therapy in CLL.

The FDA has approved pimicotinib (Pimjetmi) at 50 mg once daily for adults with symptomatic tenosynovial giant cell tumor, based on the phase 3 MANEUVER study.

Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.

Patients with relapsed or refractory CTCL who responded to denileukin diftitox-cxdl experienced improvements in skin-related quality of life and overall well-being in Study 302.

Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in oncology resources.

During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.

Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
2
Silevertinib CNS Activity Supports Planned Phase 3 in EGFR-Mutant NSCLC
3
FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutated HR+/HER2– Breast Cancer
4
NETs Year in Review: RLT Advances as Combo Strategies and ICIs Show Limited Benefit
5

